Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 4Neoplasms 3Prostatic Neoplasms 2Urogenital Neoplasms 1Radiation Pneumonitis 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Optic Neuritis 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelitis, Transverse 1Myelitis 1Myasthenia Gravis 1Lung Neoplasms 1Lung Diseases, Interstitial 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1Graft vs Host Disease 1Glioma 1Genital Neoplasms, Male 1Carcinoma, Non-Small-Cell Lung 1

Interventions

olaparib 1gallium 68 PSMA-11 1Pluvicto 1Gemcitabine 1Cisplatin 1Androgen Antagonists 1Adrenal Cortex Hormones 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Male × Adrenal Cortex Hormones × 1 year × Clear all
NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis

Phase 1/2 Active not recruiting
152 enrolled
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡